# Low-Risk Thyroid Cancer: Why Japanese Doctors Often Choose Less Aggressive Surgery

This review article from Kanaji Thyroid Hospital in Tokyo explains why Japanese doctors often treat low-risk thyroid cancer differently than their Western counterparts. Instead of routinely removing the entire thyroid gland followed by radioactive iodine treatment, Japanese surgeons frequently use more limited surgery (removing only part of the thyroid) to preserve quality of life for patients with low-risk disease. The article shares data from 1,411 patients treated at the hospital between 1993 and 2012, along with a detailed comparison of international treatment guidelines for both papillary and follicular thyroid cancers. While no single approach fits every patient, the key message is that many low-risk patients can safely avoid aggressive treatment.

# Low-Risk Thyroid Cancer: Why Japanese Doctors Often Choose Less Aggressive Surgery

## Table of Contents

- Key Points
- Understanding Thyroid Cancer and Why This Research Matters
- How Common Is Thyroid Cancer? The Numbers Behind the Disease
- Why Treatment Differs Between Japan and Western Countries
- About the Study: Two Decades of Data from Kanaji Thyroid Hospital
- Treatment for Low-Risk Papillary Thyroid Cancer
- Surgical Options: How Much of the Thyroid Should Be Removed?
- Lymph Node Dissection: A Key Difference in Practice
- To Operate or Not? The Observation Debate for Tiny Cancers
- Treatment for Low-Risk Follicular Thyroid Cancer
- Radioactive Iodine Ablation and TSH Suppression: Risks and Benefits
- What This Means for Patients
- Study Limitations: What This Review Cannot Prove
- Recommendations for Patients
- Frequently Asked Questions
- Source Information

## Key Points

- In the US, thyroid cancer incidence rose 2.4-fold from 1973 to 2002, but mortality stayed stable.
- Japanese data from one hospital: recurrence in remaining thyroid after hemi-thyroidectomy for low-risk papillary cancer was only 1%.
- Total thyroidectomy does not reduce lymph node or distant recurrence compared with hemi-thyroidectomy.
- For low-risk papillary micro-carcinoma under 1 cm, observation may be an option instead of immediate surgery.
- Western and Japanese treatment guidelines are converging: RAI ablation is questioned for low-risk patients, and total thyroidectomy is accepted for high-risk patients.

## Understanding Thyroid Cancer and Why This Research Matters

Thyroid cancer is a disease in which malignant (cancerous) cells form in the tissues of the thyroid gland, a butterfly-shaped organ located in the front of the neck that produces hormones regulating metabolism. The good news is that the most common form, **differentiated thyroid carcinoma (DTC)**, tends to grow very slowly and has a far more favorable prognosis compared with many other types of cancer.

This review focuses on a long-standing debate: how aggressively should doctors treat low-risk thyroid cancer? In Western countries, the standard approach has been **total thyroidectomy** (removal of the entire thyroid gland), followed by **radioactive iodine (RAI) ablation** — a treatment that uses radioactive iodine to destroy any remaining thyroid tissue or cancer cells. In Japan, however, a very different philosophy has taken hold.

Japanese surgeons have extensively adopted **hemi-thyroidectomy** (removal of half of the thyroid) and **subtotal thyroidectomy** (removal of most, but not all, of the thyroid). This difference matters because it affects patients' quality of life, the need for lifelong medication, and the risk of surgical complications.

Importantly, the authors note that **papillary thyroid carcinoma (PTC)** accounts for over 90% of all thyroid cancers in Japan. The majority of these patients fall into a "low-risk" category under modern risk-classification systems, and they show excellent outcomes regardless of how aggressive the initial treatment is.

## How Common Is Thyroid Cancer? The Numbers Behind the Disease

The article provides striking data on how thyroid cancer rates are changing. In the United States, the incidence of thyroid cancer increased from **3.6 per 100,000 people in 1973 to 8.7 per 100,000 in 2002** — a 2.4-fold increase, according to research by Davies and Gilbert Welch using Surveillance, Epidemiology, and End Results (SEER) program data. During the same period, however, thyroid cancer mortality remained stable, suggesting that much of the increase was due to detecting small, otherwise harmless cancers rather than a true epidemic of deadly disease.

Virtually all of this increase in the US was due to papillary carcinoma specifically, which rose from **2.7 to 7.7 per 100,000** — representing a **2.9-fold increase**. The rates of follicular, medullary, and anaplastic carcinoma — the less common types — did not change significantly.

In Japan, the picture is somewhat different. In 2003, the incidence of thyroid carcinoma in males was **3.25 per 100,000** and in females it was **9.26 per 100,000**. The age-adjusted incidence was **2.56 per 100,000 for males and 7.17 per 100,000 for females**.

Looking at the breakdown of cancer types, data from the Japanese Society of Thyroid Surgeons (JSTS) in 2004 (with Kanaji Thyroid Hospital's own figures shown in parentheses) found:

- Papillary carcinoma: **92.5%** of cases (92.0% at Kanaji)
- Follicular carcinoma: **4.8%** (5.9% at Kanaji)
- Medullary carcinoma: **1.3%** (1.0% at Kanaji)
- Anaplastic carcinoma: **1.4%** (1.2% at Kanaji)

The authors note that Japan is a "world-prominent iodine-sufficient country," and suggest that the sufficient dietary intake of iodine — largely from seaweed and seafood — may partially explain why papillary carcinoma rates differ between Japan and Western countries.

## Why Treatment Differs Between Japan and Western Countries

The treatment of differentiated thyroid cancer in Japan has traditionally followed a different path than in the West. In the United States and Europe, total or near-total thyroidectomy is performed almost routinely, followed by RAI ablation and **thyroid-stimulating hormone (TSH) suppression therapy** — giving patients thyroid hormone medication at doses high enough to keep TSH levels low, since TSH can stimulate any remaining thyroid cancer cells.

Japanese surgeons, by contrast, were slower to adopt this aggressive approach for several practical, cultural, and medical reasons:

1.
**Limited access to RAI:** Strict legal restrictions in Japan limited the number of hospitals able to administer radioactive iodine. Only patients with very advanced cancer could undergo RAI ablation.
1.
**Clinical experience:** Japanese endocrine surgeons observed that most differentiated thyroid cancers are indolent (slow-growing) and show excellent prognosis even without total thyroidectomy, RAI ablation, or TSH suppression.
1.
**Complication avoidance:** Limited thyroidectomy reduces the risk of severe complications, such as **bilateral recurrent-laryngeal nerve palsy** (paralysis of both vocal cords) and **irreversible hypoparathyroidism** (damage to the parathyroid glands, causing dangerously low calcium levels). It may also mean patients do not need to take **L-thyroxine** (thyroid hormone replacement) for life.
1.
**Different surveillance model:** Postoperative surveillance in Japan is conducted by surgeons themselves and makes extensive use of nationwide ultrasonography, which is routine and affordable — unlike in Western countries, where ultrasound is more exclusive and expensive.

The table below summarizes these socio-medical differences between Japan and Western countries:

-
**Iodine status:** Japan is a world-leading iodine-sufficient country, while many Western countries are in iodine-deficient areas
-
**Who follows patients:** Japanese surgeons conduct their own postoperative surveillance; Western patients are generally followed by internists or radiologists
-
**RAI availability:** Japan has strict legal restrictions and limited infrastructure for RAI; in the West, total thyroidectomy plus RAI ablation is standard
-
**Ultrasound access:** Japan uses ultrasonography nationwide as a routine tool; in Western countries, it remains an exclusive and expensive procedure

## About the Study: Two Decades of Data from Kanaji Thyroid Hospital

This is a **review article**, meaning it combines the authors' clinical experience with an analysis of published medical literature and international guidelines. The clinical data comes from **Kanaji Thyroid Hospital in Tokyo, Japan**, a specialized center with unusually extensive experience in treating this disease.

Between **1993 and 2012**, a total of **4,560 patients** with thyroid and parathyroid disease underwent surgical treatment at the hospital. Among them, **1,411 patients** with differentiated thyroid carcinoma underwent thyroidectomy and lymph node dissection. Distant metastases (cancer spread to other organs) appeared in **100 cases** — including 83 papillary thyroid cancers and 17 follicular thyroid cancers. Of these, there were **70 lung metastases and 30 bone and/or lung metastases**.

Since **2005**, the hospital has performed RAI therapy aggressively for patients with distant metastases and high-risk differentiated thyroid cancer. This is notable because it represents a rare situation in Japan, where most institutions have limited RAI capacity.

The authors also compared treatment guidelines from five major medical organizations — the National Comprehensive Cancer Network (NCCN), American Thyroid Association (ATA), British Thyroid Association (BTA), American Association of Clinical Endocrinologists/American Association of Endocrine Surgeons (AACE/AAES), and the Japanese Society of Thyroid Surgery/Japan Association of Endocrine Surgeons (JSTS/JAES) — against their own institutional practice at Kanaji Thyroid Hospital (established in 2010).

## Treatment for Low-Risk Papillary Thyroid Cancer

Papillary and follicular cancers are grouped together as differentiated thyroid carcinoma, but they behave quite differently. **Papillary carcinoma** tends to spread to lymph nodes in the neck. **Follicular carcinoma** is more likely to spread to distant organs through the bloodstream. Because of these differences, the authors discuss treatment recommendations for each type separately.

At Kanaji Thyroid Hospital, the standard approach for low-risk papillary carcinoma is guided by two key classifications:

-
**High-risk patients** are those with a maximum tumor diameter **greater than 5 cm**, extrathyroid extension to the mucosa of the trachea (windpipe) or esophagus, a large number of clinical lymph node metastases, lymph node metastasis **larger than 3 cm**, or the presence of distant metastasis. These patients are recommended to undergo total thyroidectomy.
-
**Low-risk patients** are those with a maximum tumor diameter **less than 2 cm** and no clinical lymph node metastasis — classified as **T1N0M0** in the TNM staging system (T refers to tumor size, N to lymph node involvement, and M to distant metastasis). For these patients, **hemi-thyroidectomy is acceptable**.

Patients who fall in between these categories are said to be in a "gray zone." However, the majority of institutions worldwide encourage total thyroidectomy for tumors larger than 4 cm or when clinical lymph node metastases are present.

## Surgical Options: How Much of the Thyroid Should Be Removed?

One of the central controversies in thyroid cancer treatment is whether removing the entire thyroid improves survival compared with removing only part of it. The authors state plainly that there is **insufficient evidence** to show that total thyroidectomy improves cause-specific survival relative to hemi-thyroidectomy in patients with papillary carcinoma.

Total thyroidectomy does prevent recurrence in the remaining (remnant) thyroid tissue, but importantly, **it does not reduce the incidence of recurrence in lymph nodes or distant metastasis**.

What do the major guidelines say? The comparison is striking:

-
**ATA guidelines (2006):** Recommend total or near-total thyroidectomy for differentiated thyroid cancer, except for low-risk micro-papillary carcinoma (tumors smaller than 1 cm).
-
**BTA guidelines (2007):** Recommend total thyroidectomy for most papillary carcinomas, especially those with a tumor diameter greater than 1 cm, multifocal disease (cancer in multiple areas), extrathyroidal extension, familial disease, history of neck irradiation, or clinical lymph node metastases.
-
**AACE/AAES guidelines:** Recommend total thyroidectomy for high-risk patients and for those with cancer in both lobes, nodules in the opposite lobe, extrathyroidal extension, or local/distant metastasis.
-
**NCCN guidelines (2008):** Accept hemi-thyroidectomy for patients with ALL of the following: age 15–45 years, no prior radiation treatment, no distant metastasis, no cervical lymph node metastasis, no extrathyroidal extension, tumors smaller than 4 cm, and no signs of aggressive variants. However, even these guidelines note that total thyroidectomy is the "most common" strategy.
-
**JSTS/JAES guidelines (2011) and Kanaji Hospital (2010):** Recommend total thyroidectomy for tumors larger than 2 cm (Kanaji) or 4 cm (JSTS/JAES), extrathyroidal extension, lymph node metastasis, or distant metastasis. Allow lobectomy for tumors under 2 cm with no lymph node or distant metastasis.

The authors point out an important weakness in Western studies claiming better outcomes with total thyroidectomy. Most patients who undergo total thyroidectomy in Western countries also receive RAI ablation therapy, meaning those studies may not have truly compared surgery alone versus surgery plus RAI. This makes it hard to know how much of the benefit comes from the surgery itself versus the radioactive iodine treatment.

Several studies have actually **failed to demonstrate any effect** of the extent of thyroidectomy on patient outcomes. Notably, a Japanese report found that the rate of recurrence in the remnant thyroid among patients with solitary T1N0M0 papillary carcinoma who underwent hemi-thyroidectomy was **only 1%** — an excellent prognosis when combined with elective lymph node dissection and no radioactive iodine therapy.

To understand the trade-offs, consider the merits and demerits of each surgical approach:

-
**Total thyroidectomy — benefits:** Easier to perform radioactive iodine therapy afterward; virtually no risk of recurrence in remnant thyroid tissue.
-
**Total thyroidectomy — drawbacks:** Postoperative hypothyroidism (patients must take thyroid hormone medication for life); risk of hypoparathyroidism (low calcium levels); risk of bilateral recurrent-laryngeal nerve paralysis (vocal cord damage).
-
**Limited thyroidectomy — benefits:** Low risk of postoperative hypothyroidism (possibly no medication needed); fewer serious complications.
-
**Limited thyroidectomy — drawbacks:** Risk of recurrence in the remnant thyroid tissue; radioactive iodine therapy is more difficult to use if needed later.

## Lymph Node Dissection: A Key Difference in Practice

Since papillary carcinoma most often recurs in lymph nodes, Japanese surgeons have historically performed **prophylactic lymph node dissection** — removing lymph nodes that do not show visible signs of cancer — more actively than their Western colleagues. This includes dissecting not only the central compartment (the area immediately around the thyroid) but also the lateral compartment (the sides of the neck).

The evidence for this practice is debated. There is **no evidence that prophylactic central compartment dissection improves cause-specific survival** for patients with papillary carcinoma. However, it does reduce the risk of relapse in lymph nodes and improves **disease-free survival** (the length of time a patient lives without signs of cancer).

Guideline recommendations vary considerably:

-
**ATA:** Prophylactic central node dissection may be performed for T3 or T4 tumors, but is not necessary for T1 or T2 tumors.
-
**BTA:** Recommends prophylactic central node dissection only for patients with high-risk features: male gender, age >45 years, tumor diameter >4 cm, or extrathyroidal disease.
-
**NCCN:** Suggests considering it for patients with one or more of: age <15 or >45 years, history of radiation therapy, known distant metastases, bilateral nodularity, extrathyroidal extension, tumor >4 cm, or aggressive variants.
-
**AACE/AAES:** Does not recommend prophylactic central node dissection.
-
**JSTS/JAES:** Notes there is currently insufficient evidence that central node dissection improves prognosis. However, because imaging often cannot detect central compartment metastasis, and reoperation for recurrence carries high risks of injury to the recurrent-laryngeal nerve and persistent hypoparathyroidism, the Kanaji authors conclude that prophylactic central compartment dissection **is** of significance — a position in sharp contrast to Western guidelines.

The authors also note that while there is no evidence that prophylactic **lateral** node dissection improves life expectancy, it reduces the risk of lymph node relapse. They recommend performing it during the **initial surgery**, because reoperation in this area carries a serious risk of complications.

## To Operate or Not? The Observation Debate for Tiny Cancers

One of the most patient-relevant questions in thyroid cancer care is whether very small cancers even need surgery at all. The widespread use of ultrasound and ultrasound-guided **fine-needle aspiration cytology (FNAC)** — where a thin needle is used to sample cells from a nodule — has led to the detection of many small, low-risk papillary micro-carcinomas (tumors smaller than 1 cm).

Davies and Welch's US data are highly relevant here: from 1973 to 2002, the incidence of thyroid carcinoma increased 2.4-fold, yet **mortality remained stable**. They concluded that this reflected increased detection of subclinical cases — small cancers that were never destined to cause harm.

In Japan, the incidence of incidentally detected thyroid carcinoma found during mass screening is reportedly **1,000-fold higher** than the incidence of overt (symptomatic) carcinoma. This means many patients are being diagnosed with cancers that may never have caused problems.

The Kanaji Hospital approach is as follows:

-
**Surgery is mandatory** for patients with papillary micro-carcinoma who have clinical lymph node metastasis detectable by palpation or imaging, or who have distant metastasis or significant extrathyroidal extension.
-
**Observation (active surveillance) may be offered** to patients without these features, after a thorough explanation of the situation and acquisition of informed consent.

The authors emphasize that Japanese studies of low-risk and incidentally detected micro-papillary carcinoma show excellent outcomes, and they call for ongoing discussion about whether simple observation or thyroidectomy should be the standard strategy for these tiny cancers.

## Treatment for Low-Risk Follicular Thyroid Cancer

Follicular thyroid carcinoma presents a unique diagnostic challenge: unlike papillary cancer, it **cannot usually be diagnosed before surgery**. Most follicular carcinomas are found only after the nodule has been removed and examined under a microscope in a postoperative pathological examination. Before surgery, patients are typically diagnosed with a "follicular tumor" or "follicular neoplasm" of undetermined significance.

The key to deciding further treatment is the **classification of the cancer as either minimally invasive or widely invasive**, based on how much the cancer has penetrated its capsule (the fibrous outer covering of the tumor) and whether it has invaded blood vessels. The degree of **vascular invasion (blood vessel involvement)** is especially important for predicting outcome.

At Kanaji Thyroid Hospital, the standard protocol is:

- For follicular neoplasms classified as "class III" with tumor size **less than 5 cm** and no distant metastasis (M0), the hospital typically performs **lobectomy** (removal of the thyroid lobe containing the nodule).
- Patients whose postoperative pathology shows **minimally invasive follicular carcinoma with no vascular invasion** (or follicular adenoma, a benign tumor) are followed with: cervical ultrasound once a year; thyroglobulin (Tg) and thyroglobulin antibody (TgAb) blood tests every 6 months; and chest CT scans every 1–2 years (for cancer cases only).
- Patients with **widely invasive carcinoma** or **minimally invasive carcinoma with significant vascular invasion** who initially had lobectomy are recommended to undergo **completion total thyroidectomy with RAI ablation** as a second surgery.
- Total thyroidectomy is also recommended for patients with **highly suspicious widely invasive carcinoma** or tumors **≥5 cm** at preoperative diagnosis.

Previous studies from Asian countries have demonstrated that widely invasive carcinoma — especially carcinoma with significant vascular invasion — has a significantly worse prognosis than minimally invasive carcinoma. A study by Ito and colleagues found that the prognostic factors for minimally invasive follicular carcinoma were:

-
**Extensive vascular invasion** (4 or more vessels involved)
- **Age ≥45 years**
- **Tumor size >4 cm**
- **Distant metastasis (M1)**

Each of these factors independently affected the risk of a patient dying from their cancer.

Guidelines differ on when completion total thyroidectomy is appropriate for follicular carcinoma:

-
**NCCN:** Recommends completion total thyroidectomy for extensive vascular invasion
-
**ATA:** Recommends it for all patients except those with tumors smaller than 1 cm
-
**BTA:** Recommends it when there is evidence of vascular invasion, tumor size >4 cm, or an oxyphilic (Hürthle cell) subtype
-
**AACE/AAES:** Recommends it for high-risk patients and those with extensive capsular or vascular invasion
-
**JSTS/JAES:** Recommends it for widely invasive carcinoma and tumors with poorly differentiated components

The authors single out **oxyphilic (Hürthle) cell carcinoma**, a variant of follicular carcinoma, for special mention. While some guidelines recommend total thyroidectomy for this type, **some Japanese studies suggest that Hürthle cell carcinoma does not have a poorer prognosis than ordinary follicular carcinoma**, indicating that treating both types the same way may be acceptable.

On the topic of **poorly differentiated carcinoma**, the WHO classification treats it as an independent histologic type. However, it is not rare for poorly differentiated components to be discovered incidentally during pathological examination of a tumor that was removed under a preoperative diagnosis of a follicular lesion. For these patients, as well as those with insular components, completion total thyroidectomy with RAI ablation is recommended at Kanaji.

## Radioactive Iodine Ablation and TSH Suppression: Risks and Benefits

Radioactive iodine (RAI) therapy has been a cornerstone of aggressive thyroid cancer treatment in Western countries. However, even the **British Thyroid Association (BTA)** guidelines now question whether RAI ablation is beneficial in **low-risk** patients, and the risk of **secondary malignancy (development of a new, different cancer)** after RAI administration has been raised as a concern.

The authors are careful to note that RAI therapy should be recommended for **high-risk** papillary thyroid cancer patients and is essential for treating distant metastases. At Kanaji Hospital, RAI has been used aggressively for high-risk disease and distant metastases since 2005.

But for low-risk patients, the Japanese view is that the risks of RAI — including the potential for a second cancer later in life — may outweigh the benefits, especially when the recurrence rate after limited surgery is as low as 1% in carefully selected patients.

## What This Means for Patients

For patients diagnosed with low-risk thyroid cancer, this review offers several important and reassuring messages:

-
**Not all thyroid cancers need aggressive treatment.** If you have a small papillary cancer (under 2 cm) with no lymph node involvement, hemi-thyroidectomy — or even active observation — may be a reasonable, safe option that preserves your quality of life.
-
**Removing the whole thyroid does not protect against lymph node or distant recurrence.** The main benefit of total thyroidectomy is preventing recurrence in the remaining thyroid tissue, and it makes RAI therapy easier if needed later.
-
**You may be able to avoid lifelong medication.** Patients who undergo limited thyroidectomy have a low risk of postoperative hypothyroidism and may not need daily thyroid hormone replacement.
-
**Watchful waiting is a legitimate option** for certain micro-carcinomas (under 1 cm) that lack concerning features.
-
**Follicular cancer is different.** If your biopsy cannot rule out follicular carcinoma, your surgeon may recommend lobectomy first, with the decision about a second surgery (completion thyroidectomy) made only after the full pathology report is available.
-
**Ask your doctor about your specific risk category.** The high-risk versus low-risk distinction directly determines whether total thyroidectomy, RAI, and TSH suppression are recommended. Understanding your T (tumor), N (node), and M (metastasis) status can help you make an informed decision.

The authors also note that therapeutic strategies in Western countries and Japan are **moving closer together**. Western guidelines now acknowledge that RAI ablation is questionable in low-risk patients, and Japanese guidelines now accept that total thyroidectomy is preferable for high-risk patients. This convergence reflects a growing international consensus that treatment should be tailored to individual risk rather than applied uniformly.

## Study Limitations: What This Review Cannot Prove

It is important to understand the limitations of the evidence presented in this review:

-
**No randomized controlled trials:** Most information on thyroid cancer outcomes comes from large patient cohorts where therapy was not randomly assigned. This means the level of evidence is generally not high, and direct comparisons between surgery types may be biased.
-
**Confounded comparisons:** In Western studies, most patients who underwent total thyroidectomy also received RAI ablation. These studies may not have genuinely compared total thyroidectomy with limited thyroidectomy as standalone treatments.
-
**Single-institution experience:** The data from Kanaji Thyroid Hospital reflects the practice and outcomes of one specialized Japanese institution, which may not be generalizable to other settings.
-
**Lack of randomized data on lymph node dissection:** A prospective randomized controlled trial of prophylactic central lymph node dissection in patients with no clinical node metastasis has not been readily feasible, leaving this question unresolved.
-
**Diagnostic limitations for follicular cancer:** Since follicular carcinoma is usually diagnosed only after surgery, preoperative risk assessment is inherently limited, and some patients may undergo a second operation.

## Recommendations for Patients

Based on this review, here are actionable points patients can discuss with their thyroid care team:

1.
**Get clear on your risk category.** Ask your doctor whether you are low-risk or high-risk, and what your exact tumor size, lymph node status, and pathology features are.
1.
**Understand your options for surgery.** If you have a low-risk papillary micro-carcinoma, ask whether hemithyroidectomy or even observation could be appropriate rather than automatically proceeding to total thyroidectomy.
1.
**Ask about lifelong medication.** If you choose limited surgery, inquire about your likelihood of needing thyroid hormone replacement. Many patients who undergo hemi-thyroidectomy retain enough thyroid function to avoid daily medication.
1.
**Discuss the pros and cons of RAI.** For low-risk disease, RAI ablation may offer little benefit and carries a small risk of secondary malignancy. For high-risk disease, it can be life-saving. Your personal risk assessment matters.
1.
**Inquire about lymph node dissection.** Ask whether prophylactic central or lateral neck dissection is recommended for your situation, and what complications (such as vocal cord paralysis or low calcium) the surgeon anticipates.
1.
**Request a follow-up plan.** If you have low-risk disease, ask about a surveillance plan using ultrasound and thyroglobulin blood tests, with the frequency tailored to your specific cancer type.
1.
**Consider a second opinion.** Given the significant differences between guideline recommendations from major organizations, it is reasonable to seek input from a thyroid cancer specialist, particularly one experienced in both aggressive and conservative management strategies.

The authors conclude that the goal of treatment should not be to maximize aggressiveness, but to **preserve quality of life** while maintaining excellent cancer outcomes. For lowrisk thyroid cancer patients, less may indeed be more.

## Frequently Asked Questions

### Is surgery always needed for a small papillary thyroid cancer?

Not necessarily. For papillary micro-carcinoma smaller than 1 cm with no lymph node spread, distant metastasis, or significant extrathyroidal extension, active surveillance (watchful waiting) may be an option after thorough discussion with your doctor. Japanese studies show excellent outcomes for low-risk and incidentally detected micro-carcinomas, even without immediate surgery.

### What is the difference between total thyroidectomy and hemi-thyroidectomy?

Total thyroidectomy removes the entire thyroid gland, while hemi-thyroidectomy removes only half. Total thyroidectomy prevents recurrence in remaining thyroid tissue but requires lifelong hormone replacement and carries higher risks of complications like low calcium or vocal cord paralysis. Limited surgery may avoid lifelong medication and has fewer serious complications, but leaves some risk of recurrence in the remaining tissue.

### Will I need to take thyroid hormone medication for life after surgery?

If you have a total thyroidectomy, you will need lifelong L-thyroxine replacement. With a limited thyroidectomy (hemi-thyroidectomy), the risk of postoperative hypothyroidism is low, and many patients keep enough thyroid function to avoid daily medication. Your doctor can estimate your likelihood of needing hormone replacement based on your surgery extent and remaining thyroid function.

### What is radioactive iodine ablation and when is it needed?

Radioactive iodine (RAI) ablation destroys remaining thyroid tissue or cancer cells after surgery. It is essential for treating distant metastases and is recommended for high-risk papillary cancer. For low-risk patients, the benefit is questionable, and it carries a small risk of developing a second cancer later in life. Japanese practice often avoids RAI for low-risk disease.

### How is follicular thyroid cancer treatment different from papillary cancer?

Follicular carcinoma is usually diagnosed only after surgery, when the nodule is examined under a microscope. Treatment depends on whether it is minimally invasive or widely invasive. For minimally invasive types with no vascular invasion, lobectomy may be enough. Widely invasive cancers or those with significant blood vessel invasion often require completion total thyroidectomy and RAI ablation.

### What are the risks of lymph node dissection during thyroid cancer surgery?

Prophylactic lymph node dissection removes lymph nodes that show no visible cancer. It can reduce the risk of lymph node relapse but does not improve cause-specific survival. The main risks of reoperation in this area are injury to the recurrent-laryngeal nerve, causing vocal cord paralysis, and persistent hypoparathyroidism, causing low calcium levels. Japanese surgeons often recommend dissection during initial surgery to avoid these higher risks later.

### Should I get a second opinion on my thyroid cancer treatment plan?

Yes. Major guidelines from Western and Japanese organizations differ significantly on surgery extent, lymph node dissection, and RAI use. Since treatment can be tailored to your individual risk, it is reasonable to seek input from a thyroid cancer specialist experienced in both aggressive and conservative strategies. A second opinion can help you understand all options for preserving quality of life while maintaining good outcomes.

## Source Information

**Original article title:** Therapeutic strategy for low-risk thyroid cancer in Kanaji Thyroid Hospital

**Journal:** Endocrine Journal 2014, 61 (1), 1–12 (Review). Submitted July 4, 2013; Accepted September 5, 2013; Released online September 25, 2013.

This patient-friendly article is based on peer-reviewed research and was written to help patients and caregivers understand the findings of the original scientific review. It is not a substitute for professional medical advice. Patients should discuss their individual treatment plans with their healthcare providers.


---
Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay.
Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact
Canonical page: https://diagnosticdetectives.com/products/low-risk-thyroid-cancer-why-japanese-doctors-often-choose-less-aggressive-surgery